Dienogest and OCPs on endometriosis-related pain

A comparative study of the effect of Dienogest and OCP on endometriosis-related pain and endometrioma size

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230509058136N1

Enrollment

100

Registered

2023-05-11

Start date

2023-06-22

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ENDOMETRIOSIS. Endometriosis

Interventions

Intervention 1: Intervention group: Treatment with Dienogest 2 mg tablets made by Aburihan company one per day and daily for up to 1 year. Intervention 2: Intervention group: Treatment with LD drug ma

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: age 16 to 40 sonography indicating endometriosis informed consent no intention of pregnancy

Exclusion criteria

Exclusion criteria: intention of pregnancy without informed consent

Design outcomes

Primary

Measure	Time frame
Pain. Timepoint: 3 month, 6 month and 12 month after. Method of measurement: visual analoug scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNiloofar Ashtari

Esfahan University of Medical Sciences

ashtarimedical@gmail.com+98 31 3668 0048

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026